News | November 15, 2010

Registry Created to Test Effectiveness of CTA

November 15, 2010 – The registry for a study designed to test the effectiveness of coronary computed tomographic angiography (CCTA) for diagnosing coronary artery disease (CAD) was announced at the American Heart Association (AHA) Scientific Session. The CONFIRM study spans six countries and will look at more than 27,000 patients.

Though the 2010 Expert Consensus on CCTA declared the evidence base “sufficiently mature” for clinical practice guidelines, CONFIRM addresses several gap areas.

“The international multicenter CONFIRM registry of more than 27,000 patients represents a highly collaborative effort of investigators at more than 12 centers who are examining the prognostic significance of coronary CT angiography findings,” said James K. Min, M.D., professor of medicine and radiology at the Cornell University Medical Center/New York Presbyterian Hospital and lead investigator of the CONFIRM registry. “The CONFIRM data definitively establish the prognostic value of CT-identified coronary artery disease and the risk of death associated with these findings. We hope that the CONFIRM data will allow for earlier detection of patients at risk for adverse coronary artery disease-related events and will result in improved treatment and outcomes of patients with coronary artery disease.”

There is a strong expectation that more long-term studies will be carried out in the future.

“CONFIRM is an important step in the validation of cardiac CT angiography,” said Matthew J. Budoff, M.D., FSCCCT, professor of medicine at the David Geffen School of Medicine at UCLA, director of cardiac CT at Los Angeles Biomedical Research Center at Harbor UCLA Medical Center and president of the Society of Cardiovascular Computed Tomography. “The size and scope of the project, coupled with the robust findings, should raise physician confidence that CT has an established role in clinical medicine.”

For more information: www.americanheart.org

Related Content

News | Cardiovascular Clinical Studies

August 12, 2022 — Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at ...

Home August 12, 2022
Home
News | Cardiovascular Clinical Studies

August 8, 2022 — Two years ago, University of Alabama at Birmingham researchers and colleagues reported that reductive ...

Home August 08, 2022
Home
News | Cardiovascular Clinical Studies

July 22, 2022 — BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by ...

Home July 22, 2022
Home
News | Cardiovascular Clinical Studies

July 18, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that ...

Home July 19, 2022
Home
News | Cardiovascular Clinical Studies

July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details ...

Home July 15, 2022
Home
News | Cardiovascular Clinical Studies

July 11, 2022 — Smoking traditional or non-combustible cigarettes while wearing a surgical mask results in a two-fold ...

Home July 12, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
News | Cardiovascular Clinical Studies

June 13, 2022 — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that ...

Home June 13, 2022
Home
News | Cardiovascular Clinical Studies

June 1, 2022 — Biofourmis, a Boston-based global leader in virtual care and digital medicine, announced that its ...

Home June 01, 2022
Home
Subscribe Now